目的　提高膀胱癌的治疗效果 ,降低膀胱癌术后复发率。　方法　 42例膀胱癌患者术后分为两组 :(1)α 干扰素 +丝裂霉素C组 2 0例 ,α 干扰素 30 0 0万IU +丝裂霉素C 40mg +生理盐水 40ml膀胱灌注 ,(2 )丝裂霉素C组 2 2例 ,丝裂霉素C 40mg +生理盐水 40ml膀胱灌注。每周 1次 ,连续 6次 ,然后每 2周 1次 ,连续 6次 ,以后每月一次连续 2年。　结果　随访 6～ 30个月 (中位数 18个月 ) ,α 干扰素 +丝裂霉素C组复发 2例 ,复发率为 10 % ,丝裂霉素C组复发 8例 ,复发率为36 % ,两组比较差别有显著性意义 (卡方检验 ,P <0 .0 5 )。　结论　α 干扰素 +丝裂霉素C膀胱灌注防治浅表性膀胱癌术后复发疗效优于单用丝裂霉素C灌注 Objective To improve the therapeutic effect of bladder cancer and reduce the recurrence rate of bladder cancer. Methods 42 cases of bladder cancer patients were divided into two groups after operation: (1) 20 patients with interferon alpha + mitomycin C, 30 patients with alpha interferon 30 million IU + mitomycin C 40mg + saline 40ml bladder Perfusion, (2) mitomycin C group 22 cases, mitomycin C 40mg + saline 40ml bladder perfusion. Once a week for 6 consecutive times, then once every 2 weeks for 6 consecutive times, once a month for 2 consecutive years. Results The follow-up ranged from 6 months to 30 months (median 18 months). The relapse rate was 10% in relapse of α interferon + mitomycin C group, 8 cases in mitomycin C group, and the recurrence rate was 36 %, The difference between the two groups was significant (Chi-square test, P <0. 05). Conclusion Intravesical instillation of α-interferon + mitomycin C is superior to mitomycin-C alone in the prevention of postoperative recurrence of superficial bladder cancer